Next-Generation Malaria Vaccination System
Legal Citation
Summary of the Inventive Concept
A comprehensive malaria vaccination system incorporating advanced nanotechnology-based delivery, synthetic adjuvants, genomics-based personalized vaccination, and gene editing tools to provide a long-lasting and durable immune response against malaria.
Background and Problem Solved
The original patent, 'Compositions and methods for generating an immune response to treat or prevent malaria', has limitations in terms of vaccine efficacy, delivery, and personalized treatment. The new inventive concept addresses these limitations by introducing advanced technologies to enhance immune response, target specific immune cells, and provide personalized vaccination.
Detailed Description of the Inventive Concept
The next-generation malaria vaccination system comprises a malaria vaccine composition and a nanotechnology-based delivery system, wherein the delivery system comprises a plurality of nanoparticles each encapsulating a recombinant viral vector. The nanoparticles are targeted to specific immune cells to enhance immune response. Additionally, the system includes a synthetic adjuvant to further enhance the immune response. The vaccine composition can be administered via a transdermal patch, providing a convenient and pain-free administration method. The system also includes a genomics-based platform for identifying an individual's genetic susceptibility to malaria, allowing for customized malaria vaccine compositions tailored to the individual's genetic profile. Furthermore, the system incorporates a gene editing tool targeted to a specific gene in the Plasmodium parasite, enabling prevention of malaria transmission.
Novelty and Inventive Step
The new claims introduce the use of nanotechnology-based delivery systems, synthetic adjuvants, genomics-based personalized vaccination, and gene editing tools, which are not present in the original patent. These advancements provide a significant improvement in vaccine efficacy, delivery, and personalized treatment, making the new inventive concept novel and non-obvious compared to the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of nanoparticles, various synthetic adjuvants, or alternative genomics-based platforms. Additionally, the gene editing tool could be targeted to different genes in the Plasmodium parasite, providing further variations of the inventive concept.
Potential Commercial Applications and Market
The next-generation malaria vaccination system has significant commercial potential in the global healthcare market, particularly in regions where malaria is prevalent. The system's advanced technologies and personalized approach could lead to increased adoption and revenue growth in the vaccine market.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/015 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K47/6901 |
| A | A61 | A61P33/06 |
| A | A61 | A61K2039/5256 |
| A | A61 | A61K2039/54 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Vaccine development, immunology, and nanotechnology for infectious disease prevention, with specific expertise in malaria vaccine design and delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced degrees in immunology or bioengineering, familiar with viral vector technologies, vaccine formulation, and emerging delivery platforms for infectious disease interventions
Obviousness Rationale
A person of ordinary skill would recognize that the PTD represents predictable extensions of the source patent's core malaria vaccine technology by applying known nanotechnology, delivery, and personalization strategies to the existing viral vector platform. The variations represent logical technological progressions that combine well-understood techniques in vaccine development to enhance efficacy, targeting, and patient-specific treatment approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,611 |
|---|---|
| Title | Compositions and methods for generating an immune response to treat or prevent malaria |
| Assignee(s) | GeoVax, Inc. |